Early Stage

Biotech company aiming to treat cancer by exploding cancer cells

Biotech company aiming to treat cancer by exploding cancer cells


Raised to Date: Raised: $766,168

Total Commitments ($USD)



Start Date


Close Date

Not Provided

Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred



SEC Filing Type

RegA+    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Distribution Model




Capital Intensity



New York, New York

Business Type


Oncolyze, with a valuation of $29.99 million, is raising funds on StartEngine through Reg A+ crowdfunding. It is a biotech company aiming to treat cancer by exploding cancer cells. The first target demographic of Oncolyze is Acute Myelogenous Leukemia (AML), and its lead drug candidate, OM-301, has generated positive results in treating AML. Oncolyze has successfully completed in vitro and in vivo experiments and significantly increases survival rates. OM-301 has also received Orphan Drug Designation from the FDA. Steven J. Evans founded Oncolyze in 2011. The current crowdfunding campaign has a maximum target of $999,998.46. The campaign proceeds will be used for pre-clinical and manufacturing, clinical trials and regulatory expenses, legal and accounting fees, and wages and salaries.

Balance Sheet

Cash and Cash Equivalents


Total Assets


Accounts Payable & Accrued Liabilities


Long Term Debt


Total Liabilities


Total Stockholders' Equity


Total Liabilities and Equity


Statement of Comprehensive Income Information

Costs & Expenses Applicable to Rev


Net Income


Earnings Per Share - Basic


Earnings Per Share - Diluted


Auditor: Fruci & Associates
Financials as of: 03/23/2023
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Oncolyze 02/07/2024 StartEngine $29,990,000 $766,168 Equity - Preferred Funded RegA+
Oncolyze 02/09/2023 SeedInvest $30,000,000 $0 Equity - Preferred Not Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


Oncolyze is a preclinical drug development company that has developed a novel drug to cure an aggressive form of leukemia called acute myeloid leukemia (AML). This type of cancer has a mortality rate of 75% within five years of a diagnosis. The company has gone through successful efficacy trials with mice and is now on the precipice of entering human clinical trials with the FDA. 

Oncolyze’s drug works by latching on to a specific protein (called HDM2) that is present on the surface of cancer cells, but not healthy cells. The drug creates holes in the cell, causing it to swell and explode. Early data has shown the drug to be very effective in mice that have been injected with live leukemia tumors transplanted from human patients. 

The company is now seeking funding to complete its safety studies in mice and move into human clinical trials. HDM2 is present on the surface of more than 25 different types of cancer. Therefore, once the drug is in the market for leukemia, Oncolyze will move on to tackle other forms of cancer.

Oncolyze has been rated a Top Deal.

Next Section: Price


I am surprised by Oncolyze’s $30 million valuation. Given the massive market upside, I would not have batted an eye if the valuation had been double. This is because Onocolyze is in a capital intensive industry. Preclinical pharmaceutical companies need major amounts of funding in order to get through the FDA approval process. Therefore, valuations tend to be much higher for these types of companies. At $30 million, I believe that this valuation is a steal.

Next Section: Market


Oncolyze will initially target an indication for acute myeloid leukemia (AML), a form of cancer with a 75% mortality rate. According to founder Steven Evans, this is a $2 billion market in the U.S. alone. However, the drug that Oncolyze has developed can potentially treat more than 25 types of cancer. All of these are massive, multibillion-dollar industries. Therefore, there is almost no ceiling on Oncolyze’s addressable market size. And that’s just in the U.S. Oncolyze plans to get approval in Europe too, which will add to the already massive market upside.

Next Section: Team


Oncolyze founder and CEO Steven Evans is a former cardiovascular medical doctor who has since succeeded in multiple entrepreneurial endeavors. He founded a medical device company called ImaCor Medical Technologies that he brought through FDA trials and secured venture capital investments for. He also served as CEO of a company with a unique radiation treatment for solid cancers. After having a conversation with Dr. Evans, I believe he has the know-how, personality, and expertise to not only lead the company through successful FDA trials, but also continue raising the funds required to give the company enough runway to get to market. 

The rest of the Oncolyze team is full of experienced medical doctors and consultants with deep expertise in the pharmaceutical and medical technology industries. 

Next Section: Differentiators


When it comes to drug development companies, differentiation is often the easiest part to explain. Usually companies are developing new and unique drugs that help treat diseases in more effective ways. That is certainly the case with Oncolyze. Its method of “exploding” cancer cells is not currently being publicly developed by any other companies. Of course, other companies could be developing similar technologies incognito. However, Oncolyze has orphan drug designation from the FDA for the acute myeloid leukemia (AML) indication. This means that no other company can bring this type of drug to market for treating AML.

Next Section: Performance


Oncolyze has extremely promising preclinical data on mice. The company has conducted the highest form of animal trials possible: transplanting live leukemia cells from human patients and injecting them into mice. And the drug worked perfectly in the mice that received it, killing the cancer cells and leaving healthy cells unharmed. This type of efficiency trial is as close as you can get to testing out the drug without actually giving it to humans. When investing in a pharmaceutical company, this is truly as good as it gets. 

Next Section: Bearish Outlook

Bearish Outlook

Let’s not lose sight of the space that Oncolyze is in. Pharmaceuticals are notoriously capital intensive, requiring millions of dollars to get to commercialization. Therefore, Oncolyze carries major funding risk. The company estimates it will take $15 million to get the drug through the first clinical trial. The first step in that process will be to complete safety trials in mice, which will cost an initial $5 million (with human trials costing $10 million). 

Additionally, there is always a chance that another pharma company (big or small) is developing the same type of drug. However, this risk is somewhat reduced since Oncolyze has orphan drug designation, which gives the drug market protection for the specific indication of acute myeloid leukemia for seven years. There’s also a risk that the clinical trials don’t go well, which could really derail the company and its prospects. 

Next Section: Bullish Outlook

Bullish Outlook

As startup investors, we love pharmaceutical companies because of the major world-changing upside that is baked into the opportunity. If Oncolyze can successfully commercialize this drug, more than 25 forms of cancer could potentially be CURED. That would change the world. CEO Steven Evans thinks that getting this product to market would be worthy of a Nobel Prize in Medicine. I couldn’t agree more. 

The company has also had multiple meetings with the FDA regarding manufacturing practices and preliminary data findings. These have all gone very well, and the company is confident it will be able to quickly bring the drug to market once approved. With extremely deadly diseases like acute myeloid leukemia (which has a 75% mortality rate), the FDA is typically far more lenient with the clinical data required to get a drug approved. This can mean a number of things, from smaller (and less expensive) trials to expedited timelines. 

All the pieces are in place for Oncolyze to be successful. If the trials do happen to go poorly, the company told us that there are a number of ways to recalibrate the drug and even immediately switch focus to other indications. 

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Oncolyze on StartEngine 2023
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $29,990,000
Price per Share: $3.21

Follow company

Follow Oncolyze on StartEngine 2023

Buy Oncolyze's Deal Report

Warning: according to the close date for this deal, Oncolyze may no longer be accepting investments.

Oncolyze Deal Report

Get KingsCrowd’s comprehensive report on Oncolyze including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Oncolyze is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Oncolyze deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge